Skip to main content
 
 
 
MENU
VISIT JANSSEN GLOBAL

EMEA
change location▼

Search
Search
COVID-19 UPDATES >

VISIT JANSSEN GLOBAL

COVID-19 UPDATES >
Janssen EMEA › Media Center

Media Center

The Media Center is intended to provide resources for media professionals only. It is not intended for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree
Cancel

Press Releases

Sep 08, 2022

TREMFYA®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study

Aug 24, 2022

Janssen Marks First Approval Worldwide for TECVAYLI®▼(teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma

Aug 04, 2022

European Commission Approves IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Jul 26, 2022

Janssen Announces New Data Supporting Safety Profile and Efficacy of Amivantamab and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer (NSCLC) and EGFR Mutations 

Jul 22, 2022

Janssen Receives Positive CHMP Opinion for Novel Bispecific Antibody TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma (RRMM)

Jun 24, 2022

Janssen Receives Positive CHMP Opinion for IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated  Chronic Lymphocytic Leukaemia (CLL)

View more Press Releases

Media Backgrounders

Neuroscience Backgrounder

Schizophrenia Backgrounder

Waldenström’s Macroglobulinemia (WM)

The Role Of The Immune System In Crohn’s Disease

Stelara MOA infographic

About Crohn’s Disease Backgrounder

VIEW MORE MEDIA BACKGROUNDERS

VIRTUAL ONCOLOGY PRESSROOM

Quick Links

 

Tweets

 
Follow us on Twitter
SUBSCRIBE TO OUR YOUTUBE CHANNEL